U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07431008) titled 'Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction' on Feb. 09.
Brief Summary: This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Study Start Date: Dec. 26, 2024
Study Type: OBSERVATIONAL
Condition:
Erectile Dysfunction
Recruitment Status: RECRUITING
Sponsor: Pharmicell Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....